Inclusion Criteria:

- Stage 1:

- Radiological or clinical evidence of a colorectal malignancy

- Requires colorectal endoscopy for diagnosis

- Stage 2:

- Histologically confirmed adenocarcinoma of the colon or rectum by colorectal
endoscopy in stage 1 study

- Resectable disease

- Planning to undergo colorectomy

- WHO performance status 0-2

- ALT ≤ 2.5 times upper limit of normal (ULN)

- Bilirubin ≤ 1.5 times ULN

- Creatinine ≤ 1.5 mg/dL

- Hemoglobin ≥ 10 g/dL (transfusion allowed for anemia due to bleeding from the tumor)

- Suitable for general anesthesia

- No active peptic ulcer disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No excessive alcohol intake (more than UK recommended limit: 28 or 21 units per week
for men or women, respectively)

- No other cancer that is currently under treatment, clinically detectable, or has been
treated within the past 5 years (other than basal cell or squamous cell carcinomas)

- At least 6 months since prior and no concurrent participation in other invasive or
drug studies

- No radiotherapy or chemotherapy within 4 weeks of endoscopic tissue sampling

- At least 24 hours since prior and no concurrent nonessential medications or
nonsteroidal anti-inflammatory drugs

- No concurrent resveratrol-containing food and drink (e.g., wine, grapes, peanuts,
mulberries, cranberries, blueberries, huckleberries)

- No concurrent vitamin supplements

- No concurrent chronic medications, including over-the-counter medications, that may
interfere with the pharmacokinetics or pharmacodynamics measured

- No concurrent medication that could interfere with biomarker assay

- No concurrent anticoagulants including, warfarin and low molecular weight heparin

- No concurrent steroids